Failing Surgical Bioprosthesis: A Challenge on the Rise

Courtesy of Dr. Carlos Fava.

The gold standard for failing aortic bioprosthesis has traditionally been surgery. However, since the first valve in valve (TAV-in-SAV) report in 2007, by Wenaweser, transcatheter valve implantation has emerged as a valid alternative. Even so, at present there is not enough scientific evidence in this regard.

Degeneración de las válvulas biológicas aórticas: un desafío cada vez más frecuente

The present study analyzed 205 patients presenting failing aortic bioprosthesis. 126 (61.5%) were reoperated (redo-SAVR) and 798 received TAV-in-SAV.


Read also: How Is Renal Function Affected by Endoprosthesis Implantation?”


Those receiving TAV-in-SAV were older, had more comorbidities, more cardiac failure and had higher STS and EurosSCORElog. After propensity score matching, the sample population was homogenized to 78 pares.

 

Mortality at 30 days and one year was numerically inferior in the TAV-in-SAV group, though it had no statistical significance (6.4% vs. 3.9% and 13.1% vs. 12.3%). Neither were there differences in stroke, AMI or need for definite pacemaker. The need for dialysis driven by acute kidney failure was numerically lower in the TAV-in-SAV group (11.5% vs. 3.8% p=0.13). Outcomes were similar across the population.

 

Hospitalization was lower in the TAV-in-SAV group (p=0.001).


Read also: TAVR in Patients with Pure vs. Mixed Aortic Stenosis: Benefits and Evolution”.


Gradients at 30 days were higher in the TAV-in-SAV group (18.1 mmHg vs. 14.3 mmHg p=0.01). This was at the expense of the Edwards valves (21.3 mmHg gradient), not with the CoreValves (15.4 mmHg) that showed no difference with redo-SAVR. The presence of >20 mmHg gradient was twice as high with the Edwards compared against the CoreValve and redo-SAVR (51.9% vs. 22.6% and 17.1%).

 

Conclusion

Patients presenting failing aortic bioprosthesis due to severe aortic stenosis treated with redo-SAVR or TAV-in-SAV have similar evolution at 30 days and one year.

 

Commentary

This group currently presents a great challenge and is being researched at the moment.

 

This retrospective study showed similar evolution in both groups, but with less hospitalization days in the TAV-in-SAV. However, a nine-day hospital stay is still high.

 

It is important to choose the right transcatheter valve, since one of these presented higher post-implantation gradients. This will certainly improve with experience and the development of new devices.

 

Gentileza del Dr. Carlos Fava.

 

Original title: Transcatheter aortic valve implantation versus redo surgery for failing surgical aortic bioprostheses. A multicenter propensity score analysis.

Reference: Marco Spaziano, et al. EuroIntervention 2017;13:1149-1156.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

TCT 2024 | TRISCEND II: A New Hope in Percutaneous Tricuspid Valve Replacement

Advanced tricuspid regurgitation (TR) is a debilitating disease associated with heart failure and increased mortality.  Edge-to-edge repair has been shown to improve both clinical condition...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Severe Tricuspid Regurgitation: Surgical vs. Transcatheter Edge-to-Edge Repair

While highly prevalent, tricuspid regurgitation is a notably undertreated valvulopathy. Its progression has been associated with higher mortality and significant disability. According to the...

ACCESS-TAVI: Comparing Post TAVR Vascular Closure Devices

Transcatheter aortic valve replacement (TAVR) is a well-established option to treat elderly patients with severe symptomatic aortic valve stenosis. Technical advances and device development...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....